Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 5/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710232 | 0.86 | NTRK1 (0.34) | LMNANTRK1RORCPARP14ACP1 | |
| SCHEMBL6710089 | 0.85 | NTRK1 (0.33) | LMNANTRK1KDM4EALDH1A1RORC | |
| SCHEMBL6833968 | 0.81 | LMNA (0.40) | LMNAKDM4EALDH1A1PKMRORC | |
| SCHEMBL6830543 | 0.78 | ALDH1A1 (0.43) | LMNAKDM4EALDH1A1PKMRORC | |
| SCHEMBL6710267 | 0.76 | RXFP1 (0.34) | KDM4EALDH1A1RORCRXFP1 | |
| SCHEMBL6707799 | 0.75 | RORC (0.35) | LMNAKDM4ERORCRXFP1 | |
| SCHEMBL6835629 | 0.74 | ALB (0.39) | LMNANTRK1DHODHALB | |
| SCHEMBL6830873 | 0.72 | LMNA (0.38) | LMNAKDM4EALDH1A1PKMALB | |
| SCHEMBL6834598 | 0.70 | SERPINE1 (0.42) | LMNAALDH1A1ALB | |
| SCHEMBL6830752 | 0.69 | ALB (0.40) | LMNAALDH1A1PKMALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | LMNA 3376/4885NTRK1 3501/4885KDM4E 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.